Home Page
Trending Articles
-
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
J Clin Oncol. 2024. PMID: 39173098
-
Advances and future directions in ROS1 fusion-positive lung cancer.
Oncologist. 2024. PMID: 39177972
-
The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance.
Cell. 2024. PMID: 39181133